TP53 and ovarian cancer: Zhang et al. [200] reported that HIF-1α may act as a mediator of the interaction between p53 and RAS signaling to participate in the cisplatin resistance in ovarian cancer and that silencing HIF-1α significantly decreased the cellular sensitivity to cisplatin.